- Home
- NMCO vs PHAR Comparison
NMCO vs PHAR Comparison
Compare NMCO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- PHAR
- Stock Information
- Founded
- NMCO 2019
- PHAR 1988
- Country
- NMCO United States
- PHAR Netherlands
- Employees
- NMCO N/A
- PHAR N/A
- Industry
- NMCO Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- PHAR Health Care
- Exchange
- NMCO Nasdaq
- PHAR Nasdaq
- Market Cap
- NMCO 603.4M
- PHAR 618.3M
- IPO Year
- NMCO N/A
- PHAR N/A
- Fundamental
- Price
- NMCO $11.18
- PHAR $8.42
- Analyst Decision
- NMCO
- PHAR Strong Buy
- Analyst Count
- NMCO 0
- PHAR 3
- Target Price
- NMCO N/A
- PHAR $27.00
- AVG Volume (30 Days)
- NMCO 207.6K
- PHAR 5.6K
- Earning Date
- NMCO 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- NMCO 5.43%
- PHAR N/A
- EPS Growth
- NMCO N/A
- PHAR N/A
- EPS
- NMCO N/A
- PHAR N/A
- Revenue
- NMCO N/A
- PHAR $285,745,000.00
- Revenue This Year
- NMCO N/A
- PHAR $20.08
- Revenue Next Year
- NMCO N/A
- PHAR $9.22
- P/E Ratio
- NMCO N/A
- PHAR N/A
- Revenue Growth
- NMCO N/A
- PHAR 30.64
- 52 Week Low
- NMCO $8.52
- PHAR $6.65
- 52 Week High
- NMCO $11.64
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- NMCO 70.31
- PHAR 40.05
- Support Level
- NMCO $10.69
- PHAR $7.95
- Resistance Level
- NMCO $10.98
- PHAR $9.35
- Average True Range (ATR)
- NMCO 0.12
- PHAR 0.52
- MACD
- NMCO 0.04
- PHAR -0.16
- Stochastic Oscillator
- NMCO 93.88
- PHAR 22.76
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.